VYNT News and Press, Vyant Bio Inc. From 04/24/23

2023-04-24 17:21:48 ET Vyant Bio ( NASDAQ: VYNT ) said its board had decided to voluntarily delist its securities from The Nasdaq Capital Market. The company said it had begun delisting and filed a Form 25 with the Securities and Exchange Commission, which is expected to becom...

CHERRY HILL, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerati...

Vyant Bio ( NASDAQ: VYNT ) said that its board decided to conduct a reduction in force as soon as practical so as to preserve cash and pursue strategic alternatives and/or wind down the company, if needed. President and CEO John Roberts and Chief Scientific Officer Robe...

Continu ing to E xplore S trategic A lternatives CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for compl...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the day with a breakdown of the biggest pre-market stock movers for Thursday! Moving stocks this morning are a reverse split, a crypto stock rally, and mo...

Vyant Bio ( NASDAQ: VYNT ) on Wednesday said it had engaged boutique investment bank LifeSci Capital to explore strategic alternatives for the company. Shares of the micro-cap biotech more than doubled in value to $1.60 after hours. Cherry Hill, N.J.-based VYNT is developing ...

CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s pro...

“Targeting specific functional rescue in a Rett patient cortical organoid disease model” CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology co...

CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company&#x...

Vyant Bio press release ( NASDAQ: VYNT ): Q3 GAAP EPS of -$0.62 beats by $0.08 . Revenue of $0.15M (-42.3% Y/Y). Shares -2.63% PM. For further details see: Vyant Bio GAAP EPS of -$0.62 beats by $0.08, revenue of $0.15M